Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching
La radiologia medica · 2025
DOI: 10.1007/s11547-025-01975-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift La radiologia medica, 2025. Verfasst von Qunfang Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, 5th Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Quinolines, Carcinoma, Hepatocellular, Phenylurea Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Innovative Research Group Project of the National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib (Len) and immune checkpoint inhibitor (ICI) in treating advanced hepatocellular carcinoma (HCC) still needs further confirmation. We aimed to evaluate the efficacy of HAIC combined with Len and ICI (HAIC + Len + ICI) versus Len alone in advanced HCC.
Methods
A total of 290 patients in Len group and 349 patients in HAIC + Len + ICI group were analysed. Propensity score matching (PSM), inverse probability treatment weighting (IPTW), and coarsened exact matching (CEM) analyses were used to balance the bias between two groups. Mediation analysis of treatment type in survival was performed for analysis.
Results
The median progression-free survival (PFS) was 5.9 ± 0.2 months in Len group and 9.2 ± 0.5 months in HAIC + Len + ICI group. The HAIC + Len + ICI group demonstrated significantly better PFS than the Len group across the entire cohort (hazard ratio [HR], 0.50; 95% CI 0.43–0.60; P < 0.001). This advantage in PFS was sustained in the PSM, IPTW, and CEM cohorts. HAIC + Len + ICI group also showed better overall survival (OS) than the Len group (HR, 0.38; 95% CI 0.31–0.46; P < 0.001). The OS was also superior in the PSM, IPTW, and CEM cohorts. The objective response rate (ORR) in HAIC + Len + ICI group was twice as high as that in Len group. Further mediation analysis showed tumor response at 3 and 6 months had different mediation effect on survival.
Conclusions
HAIC combined with Len and ICI showed improved better OS and PFS than Len alone. This triple therapy could be considered as a first-line treatment for advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology, 5th Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
- Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Dongfeng East Road 651, Guangzhou, 510260, Guangdong Province, China.
- Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Er Road, Guangzhou, 510080, Guangdong Province, China.
- Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, 61 Jiefang West Road, Changsha, Hunan Province, China.
- Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Renmin Road No. 2, Jinzhou, 121000, Liaoning Province, China.
- Department of Interventional Radiology, The Affiliated Shunde Hospital of Jinan University, Guizhou East Road 50, Foshan, Guangdong Province, China.
Förderung
- Natural Science Foundation of Guangdong Province
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Zhou, Q., Li, H., Liang, Y., Li, R., Wang, X., Wang, W., Liu, M., Duan, F., & Huang, Z. (2025). Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching. La radiologia medica. https://doi.org/10.1007/s11547-025-01975-3
Vancouver
Zhou Q, Li H, Liang Y, Li R, Wang X, Wang W, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching. La radiologia medica. 2025. doi:10.1007/s11547-025-01975-3
BibTeX
@article{Zhou2025,
author = {Zhou, Qunfang and Li, Hui and Liang, Ye and Li, Ruixia and Wang, Xiaohui and Wang, Wei and Liu, Mingyu and Duan, Feng and Huang, Zhimei},
title = {Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching},
journal = {La radiologia medica},
year = {2025},
doi = {10.1007/s11547-025-01975-3}
}
EUVIMED